Below are the small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue.
The trailing-twelve-month revenue at Neogen
NEOG is $225.21 million. Neogen's ROE for the same period is 10.59%.
The trailing-twelve-month revenue at Abaxis
ABAX is $188.77 million. Abaxis's PEG ratio is 5.40.
The trailing-twelve-month revenue at Meridian Bioscience
VIVO is $188.13 million. Meridian Bioscience's operating margin for the same period is 29.69%.
The trailing-twelve-month revenue at Quidel
QDEL is $177.66 million. Quidel's EPS for the same period is $0.42.
Loading...
Loading...
NEOGNeogen Corp
$4.74-2.47%
Edge Rankings
Momentum
3.65
Growth
3.07
Quality
N/A
Value
31.79
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
